Back to Agenda
Session 1, Tracks A, B: Regulatory and Clinical Priorities, Plans, Projects and Updates from Regulatory Authorities
Session Chair(s)
Maria Antonieta Roman
Head Regulatory Policy LaCan, Novartis, Mexico
Michelle Arguelles Gonzalez, MBA, RPH, PMP
Executive Director, Clinical Research, Merck Sharp & Dohme (MSD), Mexico
This session will provide insights and updates from various regulatory health authorities in Latin America on their current regulatory priorities, plans, projects, and updates. Gain a broader understanding of the current regulatory systems in Latin America with both clinical and regulatory perspectives presented.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize strategies and advances from Rregulatory Aagencies towards strengthening regulatory systems in their respective region
- Describe insights and best practices from regulators
- Define future perspectives, challenges, and opportunities for the regulation of biopharmaceuticals in Latin America
Speaker(s)
Noe Geovanni Garcia
Superintendente, Superintendencia De Regulación Sanitaria, El Salvador
Updates from Central America
Rian Marie Extavour, PHD, MSC, RPH
Programme Manager, Caribbean Regulatory System, Caribbean Public Health Agency (CARPHA), Trinidad And Tobago
Caribbean Regulatory System Priorities, Updates and Plans
Heriberto Enrique García Escorza, MPA, RPH
Director, Instituto de Salud Pública de Chile, Chile
Updates from Chile
Daniela Marreco Cerqueira, MS
Associate Director, Third Directorate, ANVISA, Brazil
Regulatory Priorities, Plans, Projects and Updates from ANVISA
Have an account?